Genes & Cancer

Clinical performance of E2Fs 1-3 in kidney clear cell renal cancer, evidence from bioinformatics analysis

Bin Liang1, Jianying Zhao2,3 and Xuan Wang4

1 Department of bioinformatics, Key Laboratory of Cell Biology, Ministry of Public Health and Key Laboratory of Medical Cell Biology, Ministry of Education, College of Basic Medical Science, China Medical University, Shenyang, China

2 Department of Clinical Laboratory, No.202 Hospital of PLA, Shenyang, China

3 Graduate School, Jinzhou Medical University, Jinzhou, China

4 Graduate School, Dalian Medical University, Dalian, China


Bin Liang, email:

Keywords: kidney cancer; prognosis; TCGA database; bioinformatics analysis

Received: January 04, 2017 Accepted: June 28, 2017 Published: July 03, 2017


Extensive research on the E2F transcription factor family has led to numerous insights that E2Fs were involved not only in proliferation and tumorigenesis but also in apoptosis and differentiation. In the present study, we analyzed the differential expression of E2Fs1-3 genes, and also evaluated the impact of E2Fs 1-3 genes expression on clinical outcome from the Cancer Genome Atlas (TCGA) database. The results showed that E2F1, E2F2 and E2F3 expression was increased in KIRC tissues than matched normal tissues (E2F1, P < 0.001; E2F2, P < 0.001, E2F3, P = 0.001), respectively. E2F1, E2F2 and E2F3 were significantly different in metastasis status, lymph node status, stage, and T stage in KIRC patients (all P < 0.01). E2F1 and E2F2 had the sensitivity of 96.1% and 93.1% and the specificity of 87.2% and 91.7% in discriminating KIRC from normal controls. High E2F1, E2F2 and E2F3 expression were correlated to worsen overall survival (all P < 0.01), and high E2F3 expression had worse disease free survival (P = 0.0404). Multivariate Cox regression analysis revealed that E2F1 and E2F3 were independent prognostic factors for overall survival. Taken together, E2F1 and E2F2 may serve as valuable diagnostic markers for KIRC. Moreover, E2F1, E2F2 and E2F3 could provide valuable prognostic information for KIRC patients.

PII: 143